Protalix BioTherapeutics, Inc.
About Protalix BioTherapeutics, Inc.
Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $52.7M
- Net income
- -$6.6M
- Total assets
- $82.3M
- Market cap
- $160.3M
- Gross margin
- 48.8%
- Operating margin
- -10.4%
- Net margin
- -12.5%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $52.7M
- Cost of revenue
- $27.0M
- Gross profit
- $25.8M
- Operating expenses
- $31.3M
- Operating income
- -$5.5M
- Income tax
- $996.0K
- Net income
- -$6.6M
- EPS (basic)
- $-0.08
- EPS (diluted)
- $-0.08
Balance sheet
- Total assets
- $82.3M
- Current assets
- $66.7M
- Total liabilities
- $34.1M
- Current liabilities
- $26.5M
- Shareholders’ equity
- $48.2M
Cash flow
- Operating cash flow
- -$12.0M
- Investing cash flow
- -$2.4M
- Financing cash flow
- $9.3M
- Net cash flow
- -$5.0M
Statements via Polygon.io (SEC filings)
- Market cap
- $160.3M
- EPS (diluted)
- $-0.08
- Shares outstanding
- 81.8M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jan 2, 1996
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $6.6M in FY2025.
- Revenue grew 38% from FY2021 to FY2025.
- Gross margin of 48.8%, net margin -12.5%.
- Trading 38% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Protalix BioTherapeutics, Inc..
Write a review
News about Protalix BioTherapeutics, Inc.
News & sentiment via Polygon.io
